Clinical Trial Search

Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…

Primary: Negative Polymerase Chain Reaction (PCR) — 2; 7 Participants

Primary: Number of Participants With National Early Warning Score (NEWS) Change From 3 to 0 — 44; 29 Participants

Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants

Primary: SARS-CoV-2 Infection — 4; 2 Participants

Primary: Severity of COVID-19: Evaluation of the Severity of COVID-19 as Measured by the Maximum Difference From the Baseline Value in the OSCI Within 28 Days From the Start of…

Primary: Participants Enrolled — 36 Participants

Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants

Primary: Number of Participants With Non-serious and Serious Adverse Events During Trial — 0; 0; 0; 0 Participants

Primary: Number of Composite Primary End Point (Critical Care Admission, Palliative Discharge When Discharged From Hospital, or Mortality Within the 6 Weeks After Diagnosis of…

Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…

Primary: Change of Arterial Oxygenation at 48 Hours From Enrollment — 200; 183 ratio

Primary: Number of Patients With Early Clinical Improvement — 111; 80 Participants — p=<0.03

Primary: Number of Participants With Symptomatic COVID-19 at 60 Days — 24; 19 Participants — p=0.52

Primary: Percent of Healthcare Workers Testing Positive for COVID-19. — 0; 0 percentage of healthcare workers

Primary: Duration of Hospital Stay — 3.9; 2.1 days

Primary: Motor Balance as Measured by Timed Up and Go (TUG) — 20.57 seconds

Primary: Number of Participants With Adverse Events — 5; 9; 10; 8 Participants

Primary: Ordinal Outcome Scale - Day 7 — 5; 5; 9; 13 Participants

Primary: Body Temperature — 98.1 degrees Fahrenheit

Primary: Proportion of Patients Alive and Free of Respiratory Failure Through the 30-day Trial. — 100 Percentage of of patients alive and free

Primary: Number of Participants Intubated During Hospitalization — 8; 25 Participants — p=0.297

Primary: Efficacy of Treatment at Day 28 as Assessed by Number of Participants Who Develop SARS-Cov-2 Infection — 12; 13 Participants — p=0.42

Primary: Measure of Daily Stool Frequency for Patients With COVID Treated With Bismuth — 3 bowel movements

Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 19; 28…

Primary: Number of Participants With Each Score on WHO 7-point Outcome Scale at Day 7 — 6; 0; 20; 8 Participants — p=0.0346

Primary: Proportion of Participants With Treatment-related Serious Adverse Events (tSAEs) — 0; 0 proportion of participant

Primary: Deterioration Resulting in Healthcare Review — 10 alerts generated

Primary: Reinfection With SARS-CoV-2 — 12; 77; 68; 957 Participants

Primary: Number of New COVID 19 Infections — 25; 21 Participants